Chinese biotech firm HighTide Therapeutics slashes Hong Kong

Shenzhen-based HighTide Therapeutics is aiming to raise HK$278 million (US$35.6 million) from an IPO in Hong Kong, a fraction of the originally planned US$200 million.

Related Keywords

Guangdong , Jilin , China , Indonesia , Hong Kong , Cainiao , China General , Huatai , Jiangxi , Indonesian , Chinese , Mayer Brown , Jerome Powell , Cangzhou Chuangrong , Alibaba Group Holding , Yuthai Fund , Yuexiu Fund , Huatai International , Federal Reserve , China Development Bank Capital , Healthcare Fund Of Guangdong , Hong Kong Exchanges , Robert Lui , Deloitte China , Chairman Jerome Powell , Hang Seng Index , China Development Bank , Ipo , Hightide , Hang Seng ,